Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao M-S
Safety and Tolerability Cerebrolysin: Well-Established Safety Profile Cerebrolysin benefits from decades of post-marketing surveillance and clinical trial safety data: Clinical Trial Safety: Across multiple RCTs, Cerebrolysin has demonstrated a tolerability profile comparable to placebo in most studies, with adverse events generally mild and transient Common Side Effects: Injection site reactions, dizziness, headache, and nausea are the most frequently reported adverse events at standard clinical doses Serious Adverse Events: Rare at therapeutic doses
Peptides Peptides, which are short chains of amino acids, are revolutionizing health and wellness by offering targeted, highly specific treatments that support a wide range of physiological processes
These dietary choices limit natural sources of B12 to animal products, leading to deficiencies in up to 90% of people adhering to these diets